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ABSTRACT
Objective To investigate socioeconomic inequalities in
outcome of pregnancy associated with Down syndrome
(DS) compared with other congenital anomalies screened
for during pregnancy.
Design and setting Retrospective population-based
registry study (East Midlands & South Yorkshire in
England).
Participants All registered cases of DS and nine
selected congenital anomalies with poor prognostic
outcome (the UK Fetal Anomaly Screening Programme
(FASP)9) with an end of pregnancy date between
1 January 1998 and 31 December 2007. Main outcome
measures: Poisson regression models were used to
explore outcome measures, including socioeconomic
variation in rates of anomaly; antenatal detection;
pregnancy outcome; live birth incidence and neonatal
mortality. Deprivation was measured using the Index of
Multiple Deprivation 2004 at super output area level.
Results There were 1151 cases of DS and 1572 cases
of the nine severe anomalies combined. The overall rate
of antenatal detection was 57% for DS, which
decreased with increasing deprivation (rate ratio
comparing the most deprived tenth with the least
deprived: 0.76 (0.60 to 0.97)). Antenatal detection rates
were considerably higher for FASP9 anomalies (86%),
with no evidence of a trend with deprivation (0.99 95%
CI (0.84 to 1.17)). The termination of pregnancy rate
following antenatal diagnosis was higher for DS (86%)
than the FASP9 anomalies (70%). Both groups showed
wide socioeconomic variation in the termination of
pregnancy rate (rate ratio: DS: 0.76 (0.58 to 0.99);
FASP9 anomalies: 0.80 (0.65 to 0.97)). Consequently,
socioeconomic inequalities in live birth and neonatal
mortality rates associated with these anomalies arise
that were not observed in utero.
Conclusions Socioeconomic inequalities exist in the
antenatal detection of DS, and subsequent termination
rates are much higher for DS than other anomalies.
Termination rates for all anomalies are lower in more
deprived areas leading to wide socioeconomic
inequalities in live born infants with a congenital
anomaly, particularly DS, and subsequent neonatal
mortality.
INTRODUCTION
Although only 2–3% of UK pregnancies are
affected by congenital anomalies, they impact dis-
proportionately on mortality, with almost 30% of
neonatal and infant deaths attributable to anomaly
causes.1 2 Consequently, primary preventative mea-
sures have become integral to antenatal care,
together with considerable investment in antenatal
screening, resulting in the implementation of the
UK Fetal Anomaly Screening Programme (FASP) in
2010.3 This aims to identify 11 anomalies: serious
cardiac, anencephaly, trisomies 13 and 18, spina
biﬁda, exomphalos, renal agenesis, lethal skeletal
dysplasia, congenital diaphragmatic hernia, cleft lip
and gastroschisis. The ﬁrst nine present an
extremely poor prognosis (FASP9), while cleft lip
and gastroschisis require early surgical intervention.
All are detectable by antenatal ultrasound, with
screening offered to women between 18+0 and
20+6 weeks’ gestation. The detection of a poten-
tially lethal fetal anomaly permits the option of
termination of pregnancy.
Previous examination of the FASP9 anomalies
found no difference in occurrence rates in utero or
antenatal detection by socioeconomic deprivation.4
However there were lower rates of termination
demonstrated in areas of higher deprivation. The
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What is already known on this topic?
▸ Rates of antenatal detection of nine nationally
audited anomalies with a poor prognostic
outcome are similar for all deprivation groups.
▸ Variations in rates of termination of pregnancy
have led to socioeconomic inequalities in the
rates of live birth associated with congenital
anomaly and neonatal mortality.
▸ Little is known about the impact of
socioeconomic deprivation on antenatal
detection and termination of pregnancy for
Down syndrome (DS).
What this study adds?
▸ Rates of antenatal detection of DS are much
lower than for other anomalies and are lower
in more deprived areas.
▸ Rates of termination of pregnancy are higher
for DS than other anomalies, but are
signiﬁcantly lower among women from more
deprived areas.
▸ The combination of these factors results in
extremely wide socioeconomic inequalities in
relation to birth with congenital anomalies,
especially DS, and subsequent mortality.
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consequent outcome is variation, with socioeconomic depriv-
ation, in the number of live born infants with one of these
anomalies, which, together with associated mortality and mor-
bidity, offers an explanation for the inequalities seen nationally.4
Antenatal detection of Down syndrome (DS) in England
differs, since a separate national screening system exists and add-
itional methods of diagnosis are employed. While associated
soft markers may be suspected during the initial booking scan,
the majority of cases have historically been diagnosed following
later uptake of blood tests or more invasive procedures. Cases
of DS outnumber each of the FASP anomalies and are associated
with a high rate of pregnancy termination.5
Congenital anomaly data are collated by a number of regional
registers, permitting consideration of inequalities in outcome
from antenatal diagnosis through to the end of pregnancy and
neonatal mortality associated with anomalies. Registers cover
only 34% of England and all of Wales, with signiﬁcant geo-
graphical areas, including London and the South-East, lacking
any form of routine surveillance. This has implications not only
for monitoring trends in the occurrence of anomalies, but also
in service planning.
Data from a large English congenital anomaly register (∼10%
of births in England) are used here to explore relative socio-
economic inequalities in DS and the FASP9 anomalies.
METHODS
The population-based East Midlands and South Yorkshire
Congenital Anomalies Register (EMSYCAR) records congenital
anomalies in fetuses and infants of mothers living within the
region at the time of delivery, monitoring approximately 60 000
births annually (excluding Northamptonshire, which joined in
2002). Data on live births, spontaneous fetal losses and still-
births (before or after 24 weeks’ gestation), and terminations of
affected pregnancies at any gestation were provided, using mul-
tiple sources of case ascertainment from the care pathway,
including prenatal ultrasound and screening, delivery reports,
birth notiﬁcations, pathology, cytogenetics, clinical genetics,
neonatal medicine and paediatric surgery. All fetuses registered
with either DS (trisomy 21) or one of the FASP9 anomalies in
pregnancies ending between 1 January 1998 and 31 December
2007 were included.
FASP9 anomalies included only those conditions where the
International Classiﬁcation of Diseases (ICD)-10 code uniquely
identiﬁed an anomaly with a high degree of certainty of an
adverse prognosis; two chromosomal (trisomies 13 and 18) and
seven non-chromosomal anomalies (anencephaly, spina biﬁda,
hypoplastic left heart, bilateral renal agenesis, lethal skeletal dys-
plasia, diaphragmatic hernia and exomphalos) met this criterion.
Where fetuses were registered with a chromosomal diagnosis,
coexisting anomalies were deemed secondary to the underlying
problem. The deﬁnition of ‘antenatally detected’ followed
European Congenital Anomaly Surveillance System (EUROCAT)
guidelines, determined by the earliest suggestion of the precise,
or closely related, anomaly, or identiﬁcation of an antenatal soft
marker ‘nearly 100% predictive’ of the anomaly present at
delivery. The presence of a soft marker alone (eg, ‘raised nuchal
translucency’) is insufﬁcient evidence of DS; however, DS can
be considered antenatally detected using EUROCAT guidelines
in the absence of invasive testing if multiple clinical signs are
present, and termination of pregnancies are indeed performed
on this basis. Similarly, FASP9 anomalies can be considered
present based on clinical ﬁndings without a postmortem result.
Live birth denominators were obtained from the Ofﬁce for
National Statistics and stillbirths from the Centre for Maternal
and Child Enquiries (CMACE) by year of birth, mother’s age and
tenth of deprivation of mother’s residence at delivery.
Deprivation was measured by the Index of Multiple Deprivation
20046 comprising seven domain indices at the super output area
level (income, employment, health and disability, education,
skills and training, housing and services, living environment and
crime). Super output areas are the smallest areas for which these
deprivation data are available, their small size (1500 residents)
limiting the heterogeneity within them. All super output areas in
England were ranked by deprivation score and divided into 10
groups with roughly equal numbers of births, from 1 (least) to 10
(most deprived). The mother’s postcode at delivery was located
within a super output area and the deprivation score for this area
was applied to her. Analyses were undertaken at the individual
case (fetus or baby) level. Poisson regression models7 were used
to assess trends in the six outcome measures by deprivation tenth
before and after adjustment for year of birth and maternal age:
1. Rate of anomalies in utero (all cases of selected anomalies
whenever identiﬁed) (denominator: total live births, still
births and known late fetal losses and terminations of preg-
nancy with a fetal anomaly)
2. Rate of antenatal detection (denominator: all cases of
anomalies)
3. Rate of termination of pregnancy for anomaly (denomin-
ator: antenatally detected cases)
4. Rate of fetal loss or stillbirth with an anomaly (denominator:
total live births, stillbirths and known late fetal losses regis-
tered with a fetal anomaly)
5. Rate of live births with an anomaly (denominator: total live
births)
6. Rate of neonatal mortality of infants with an anomaly
(denominator: total live births).
Models were ﬁtted for DS versus all FASP9 anomalies com-
bined. Models were then ﬁtted for the FASP9 chromosomal and
non-chromosomal anomalies separately. Interactions were
explored to assess the change in the effect of deprivation over
time. We included maternal age (grouped <20, 20–24, 25–29,
30–34, >35 years) in the models to assess its inﬂuence on any
observed socioeconomic inequality. Two-sided signiﬁcance
testing was used. Conﬁdence limits were obtained with the delta
method.8 The effect of gestational age at detection of anomaly
on termination of pregnancy was also assessed (<17, 18–21,
22–23, >24 weeks’ gestation).
RESULTS
Between 1998 and 2007, there were 1151 registrations of DS
with full postcode and maternal age information, and 1695
further registrations of FASP9 anomalies, representing 1472
fetuses with a single FASP9 anomaly and 107 fetuses with two
or more, making 1579 fetuses in total. Of these, seven also had
DS and were included only in that group, leaving 1572 cases.
Overall antenatal detection rates (table 1) were much lower
for DS (57%) than the FASP9 anomalies (86%) (p<0.0001)
which varied from 77% for diaphragmatic hernia to 97% for
anencephaly. Subsequent rates of termination following ante-
natal diagnosis were much higher for DS (86%) than the overall
rate for FASP9 anomalies (70%) (p<0.0001) with anencephaly
being the only individual anomaly to exceed the DS rate (88%).
The difference in antenatal detection rates between DS and
FASP9 cases resulted in a much higher proportion of DS regis-
trations ending in live birth (45%) compared with FASP9 anom-
alies (30%) (p<0.0001), despite the higher termination rate.
However, neonatal mortality for DS was extremely low (1%)
compared with 10% for the FASP9 anomalies (p<0.0001).
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Poisson regression models (table 2) showed DS registrations
were signiﬁcantly lower in more deprived areas (rate ratio com-
paring the most deprived with the least deprived tenth: 0.55
(0.46 to 0.66)). After adjusting for maternal age, no evidence of a
trend with deprivation remained (rate ratio (RR) 1.04 (0.86 to
1.25)), with rates similar across the deprivation tenths. This
pattern echoed the two FASP9 chromosomal anomalies. For non-
chromosomal anomalies, however, the registration rate increased
with increasing deprivation (RR 1.41 (1.17 to 1.70)). Overall,
there was no evidence of a variation in registration rates with
deprivation for the FASP9 anomalies (chromosomal and non-
chromosomal combined) (RR 1.05 (0.90 to 1.23)). The ﬁtted
models showed no evidence of any two-way interactions.
Similarly, no evidence of variation in antenatal detection rates
of the FASP9 anomalies with deprivation emerged (adjusted RR
0.99, 95% CI (0.83 to 1.18)). This was true for both chromo-
somal and non-chromosomal FASP9 anomalies (table 2). In con-
trast, rates of antenatal detection for DS did vary with
deprivation (adjusted RR 0.77 (0.58 to 1.01)) being lower in
the most deprived areas (45%) compared with the least deprived
(60%) although this was not statistically signiﬁcant. A slightly
lower proportion of cases from the least deprived areas was
detected before 22 weeks’ gestation compared with those from
the most deprived areas, though this was not signiﬁcant (DS:
0.90 (0.69 to 1.19); FASP9: 0.90 (0.74 to 1.08)).
Following antenatal detection, termination of pregnancy rates
varied with socioeconomic deprivation for both DS and the
FASP9 anomalies. The difference in termination rates between
the most and least deprived areas was similar for both anomaly
groups (adjusted RR: DS: 0.77 (0.58 to 1.01); FASP9 anomal-
ies: 0.79 (0.64 to 0.98)) and showed little change after adjusting
for maternal age. However, in absolute terms, there was a wider
gap in termination rates for DS (least deprived 91%; most
deprived 67%) than for the FASP9 anomalies (least deprived
72%; most deprived 57%). Rates of stillbirth and fetal loss were
high (see table 1) but did not differ signiﬁcantly for either DS
or FASP9 with socioeconomic deprivation (adjusted RR DS:
0.60 (0.27 to 1.35); FASP9: 1.58 (0.94 to 2.66)).
Consequently, live birth and neonatal mortality rates showed
marked socioeconomic variation. For DS, the age-adjusted rate
ratio between the most and least deprived cases increased from
1.04 (0.86 to 1.25) for total registrations to 1.88 (1.42 to 2.49)
for live births and 6.00 (1.09 to 33.2) for neonatal deaths,
although absolute numbers of deaths were small. The FASP9
group exhibited a similar but less marked pattern, with the
age-adjusted rate ratio increasing from 1.22 (1.04 to 1.44) for
total registrations to 1.85 (1.37 to 2.50) for live births and 2.23
(1.31 to 3.78) for neonatal deaths.
DISCUSSION
Socioeconomic deprivation inﬂuences the antenatal detection
rate of DS but not the nine severe anomalies screened for by
FASP. Some evidence suggests that this inequality arises not only
from uptake, but also the offer of screening9 with deprivation
associated with a lower chance of screening being offered. Once
detected, rates of termination of pregnancy were much higher
for DS than the FASP9 anomalies, although both groups showed
wide socioeconomic differences. These disparities impact on
socioeconomic inequalities observed in live births with a congeni-
tal anomaly and, for the severe anomalies, the subsequent neo-
natal mortality. Although there is a signiﬁcant body of
quantitative data investigating the variables associated with the
decision to continue or terminate an affected fetus,10–17 the com-
plete pathway from antenatal diagnosis through to pregnancy
outcome has been sparsely researched, a major difﬁculty being
the lack of detailed, routinely recorded, relevant data.
Antenatal suspicion of a FASP9 anomaly originates either
during the ﬁrst trimester dating scan following pregnancy
booking or the fetal anomaly scan, usually conducted between
18 and 21 weeks’ gestation. While such scans may represent
‘informed’ acceptance of screening services, they are widely
regarded as an opportunity to date a pregnancy, estimate the
date of delivery, visualise and obtain a photograph of the devel-
oping fetus18 19 and they are frequently considered routine.20–23
In contrast, antenatal diagnosis for DS is offered via a deﬁned
screening programme involving separate, and conscious, uptake
of blood tests and/or invasive procedures.
In the UK, most National Health Service trusts now routinely
offer combined ﬁrst trimester screening for DS and other
chromosomal anomalies, including ultrasound measurement of
Table 1 Number of registered cases, antenatal detection rate and outcome of pregnancy by anomaly, 1998–2007
Selected anomalies ICD code
Total
cases
Antenatal
detection
% (n)
Termination of
pregnancy of those
antenatally
detected % (n)
Outcome of pregnancy for all cases % (n)
Termination of
pregnancy
Fetal losses
and stillbirth
Live births
(surviving
>28 days)
Neonatal
death
Down syndrome (DS) Q900-9 1151 57% (657) 86% (566) 49% (566) 6% (65) 44% (505) 1% (15)
Anencephaly Q000 257 97% (249) 88% (218) 85% (218) 8% (20) 0% (1) 7% (18)
Spina bifida Q050-Q059 339 90% (303) 78% (235) 70% (235) 6% (20) 22% (75) 2% (8)
Hypoplastic left heart Q234 171 85% (146) 56% (82) 48% (82) 8% (14) 25% (42) 19% (33)
Bilateral renal agenesis Q601/606 59 81% (48) 85% (41) 69% (41) 15% (9) 0% (0) 15% (9)
Lethal skeletal dysplasia Q771-3 45 82% (37) 57% (21) 47% (21) 7% (3) 33% (15) 13% (6)
Diaphragmatic hernia Q790 183 77% (140) 29% (40) 22% (40) 8% (14) 47% (86) 23% (43)
Exomphalos Q792 230 85% (195) 56% (109) 47% (109) 15% (34) 34% (77) 4% (10)
Trisomy 18 Q910-13 285 85% (242) 81% (196) 69% (196) 13% (38) 6% (18) 12% (33)
Trisomy 13 Q914-7 127 84% (107) 83% (89) 70% (89) 16% (20) 5% (6) 9% (12)
All FASP9 selected anomalies
(excl. DS cases)
1572 86% (1351) 70% (939) 60% (939) 10% (157) 20% (316) 10% (160)
All other registered anomalies 10 857 – – 9% (953) 4% (486) 84% (9075) 3% (343)
Total registered anomalies 13 580 – – 18% (2458) 5% (708) 73% (9896) 4% (518)
FASP, the UK Fetal Anomaly Screening Programme; ICD, International Classification of Diseases.
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the nuchal thickness of the developing fetus between 11 and
13 weeks. There is some suggestion that access to this relatively
new technology, and the earlier diagnosis it facilitates, varies geo-
graphically24 and is often accessed privately. During the study
period, there was inevitable variation between trusts across the
region in the precise screening method offered and the imple-
mentation of changes, but there is no suggestion that access to
prenatal care differed between deprived or more afﬂuent areas.
Wide variation in the antenatal detection of DS exists where
national screening is offered in Europe, with England and Wales
having one of the lowest rates of detection at 66%. In France,
this ﬁgure has reached 90%, with Khoshnood et al25 indicating
that this has led to a considerable reduction in inequalities.
Rates of pregnancy termination following antenatal detection
of DS were much higher than other anomalies, despite DS
having near-normal life expectancy, particularly in the absence
of any cardiac defect, and the lowest neonatal mortality rate of
the selected anomalies. Since it is more prevalent than other
anomalies, pregnant women may not only have greater aware-
ness of the condition but their screening uptake may reﬂect a
premeditated decision to respond to a positive anomaly diagno-
sis by terminating their pregnancy26 27 with those women for
whom termination is not an option being less likely to enter the
screening process.26 Attitudes towards learning disability will be
relevant, since the clinical likelihood of a live born child surviv-
ing with DS is much higher than the FASP9 anomalies.
Rates of termination of pregnancy for all anomalies are lower
in more deprived areas. Since later diagnosis is associated with
lower rates of termination16 28 and evidence suggests a correl-
ation between later presentation and increased deprivation,29 30
the options available to women living in more deprived areas
may be more restricted should a serious anomaly, particularly
DS, be detected. Difﬁculties in expressing and understanding
risk are well documented20 with socioeconomic variation in
both the communication by health professionals and the inter-
pretation by parents. Evidence suggests that anecdotal reports of
women’s experiences surrounding the decision to continue a
pregnancy after an antenatal diagnosis of a fetal anomaly are
supported by real differences in counselling attitudes and proce-
dures between the various clinical professionals subsequently
involved.31 Such differences are likely to display geographic and
socioeconomic variation. Further research is needed to under-
stand whether the socioeconomic variation in rates of termin-
ation of pregnancy demonstrated here arises partly from
differences in the communication process or the interpretation
of risk and subsequent decision making by parents.
Limitations
Data from antenatal diagnosis through to postnatal outcome are
unavailable nationally in the UK, and limited elsewhere to regis-
ters belonging to the European Congenital Anomaly
Surveillance System (http://www.eurocat-network.eu). Although
our data are regional, analysis over a decade, with over 600 000
births (around 10% of the births in England) provides conﬁ-
dence that results are generally applicable elsewhere in the UK
and in countries with similar policies on antenatal care and
pregnancy termination. While we lack detailed data on individ-
ual deprivation measures, possibly attracting problems of con-
founding, our methods using area-level deprivation data are
straightforward and demonstrate how congenital anomaly regis-
ter data may be used to monitor trends in antenatal detection,
termination, live births and mortality.
Only FASP9 conditions where the ICD-10 code uniquely
identiﬁed an anomaly for which there was a high level of
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certainty about an adverse prognosis were analysed. However,
due to a lack of additional information, there still remained vari-
ation in prognosis for conditions such as spina biﬁda and exom-
phalos. Similarly, due to small numbers, we could not look at
speciﬁc outcomes for cases exhibiting multiple anomalies. If
severity or presence of multiple anomalies was not linked to
socioeconomic deprivation, then this would not impact on the
ﬁndings seen here. Any trend of increasing severity with increas-
ing deprivation would lead to an underestimate of the socio-
economic effect we have identiﬁed.
Implications
Uniform provision of DS screening in the UK is urgently
required to reduce socioeconomic inequalities in antenatal
detection, which has been achieved elsewhere.27 Furthermore,
understanding the complex reasons underlying socioeconomic
variations in termination rates for congenital anomaly is essen-
tial to assess the extent to which they could result from system-
atic differences in access to services, and communication and
interpretation of risk. While the decision to continue an
anomaly-affected pregnancy should never be regarded as a
ﬂawed choice, an inevitable consequence is an increased concen-
tration of congenital anomalies, particularly DS, together with
associated learning difﬁculties, cardiac problems and other
complex health needs, among the most deprived socioeconomic
groups. This carries obvious implications for integration of
health and social care, and maintaining awareness of these
trends is essential to ensure adequate service provision. We
therefore urge that existing UK regional anomaly registers be
safeguarded, and the current network expanded into areas not
presently covered, to permit monitoring of future trends.
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